Criteria | Antipsychotics [20] | Bronchiolitis | Visual Acuity [21] |
---|---|---|---|
Population | Children and young adults aged ≤ 24 years experiencing a psychiatric disorder or behavioral issues outside the context of a disorder | Infants and young children aged < 24 months experiencing their first episode of wheeze or diagnosed with bronchiolitis or RSV | Community-dwelling adults aged ≥ 65 years with unrecognized impaired visual acuity or vision-related functional limitations |
Intervention | Any Food and Drug Administration-approved first- or second-generation antipsychotic | Any bronchodilator, any corticosteroid, hypertonic saline, oxygen therapy, antibiotics, heliox | Vision screening tests (alone or within multicomponent screening/assessment) performed by primary healthcare professionals |
Comparators | Placebo, no treatment, any other antipsychotic, the same antipsychotic in a different dose | Placebo, usual care, no treatment, normal saline, or another intervention of interest | No screening, delayed screening, attention control, screening involving all components of intervention except vision component, usual care |
Outcomes | Intermediate and effectiveness outcomes, adverse effects and major adverse effects, adverse effects limiting treatment, specific adverse events, persistence and reversibility of adverse effects | Outpatient admissions, inpatient length of stay, change in clinical score, oxygen saturation, respiratory rate, heart rate, pulmonary function, adverse events, escalation of care, length of illness, duration of oxygen therapy | Benefits (e.g., mortality, adverse consequences of poor vision), harms (e.g., serious adverse events), implementation factors (e.g., uptake of referrals) |
Study designs | RCTs and nRCTs, controlled cohort studies, controlled before-after studies | RCTs | RCTs, controlled experimental and observational studies |